A mass spectrometry assay for detection of endogenous and lentiviral engineered hemoglobin in cultured cells and sickle cell disease mice
The Journal of Gene Medicine · 2024
DOI: 10.1002/jgm.3567 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Gene Medicine, 2024. Verfasst von Xuejun Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. Hauptthemen laut MEDLINE: Lentivirus, Anemia, Sickle Cell. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 72 Literaturangaben. Gefördert von: Midwest Athletes Against Childhood Cancer, Caragher Family, Greater Milwaukee Foundation.
Abstract (Originalsprache)
Sickle cell disease (SCD) results from a sequence defect in the β ‐globin chain of adult hemoglobin (HbA) leading to expression of sickle hemoglobin (HbS). It is traditionally diagnosed by cellulose‐acetate hemoglobin electrophoresis or high‐performance liquid chromatography. While clinically useful, these methods have both sensitivity and specificity limitations. We developed a novel mass spectrometry (MS) method for the rapid, sensitive and highly quantitative detection of endogenous human β ‐globin and sickle h β ‐globin, as well as lentiviral‐encoded therapeutic h β AS3‐globin in cultured cells and small quantities of mouse peripheral blood. The MS methods were used to phenotype homozygous HbA (AA), heterozygous HbA–HbS (AS) and homozygous HbS (SS) Townes SCD mice and detect lentiviral vector‐encoded h β AS3‐globin in transduced mouse erythroid cell cultures and transduced human CD34 + cells after erythroid differentiation. h β AS3‐globin was also detected in peripheral blood 6 weeks post‐transplant of transduced Townes SS bone marrow cells into syngeneic Townes SS mice and persisted for over 20 weeks post‐transplant. As several genome‐editing and gene therapy approaches for severe hemoglobin disorders are currently in clinical trials, this MS method will be useful for patient assessment before treatment and during follow‐up.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
- Department of Medicine, Division of Hematology-Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
- Department of Medical Microbiology, Immunology and Cell Biology, Southern Illinois University School of Medicine, Springfield, Illinois, USA.
- Department of Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Förderung
- Midwest Athletes Against Childhood Cancer
- Caragher Family
- Greater Milwaukee Foundation
Zitieren
APA
Wang, X., McKillop, W. M., Dlugi, T. A., Faber, M. L., Alvarez-Argote, J., Chambers, C. B., Wilber, A., & Medin, J. A. (2024). A mass spectrometry assay for detection of endogenous and lentiviral engineered hemoglobin in cultured cells and sickle cell disease mice. The Journal of Gene Medicine. https://doi.org/10.1002/jgm.3567
Vancouver
Wang X, McKillop WM, Dlugi TA, Faber ML, Alvarez-Argote J, Chambers CB, et al. A mass spectrometry assay for detection of endogenous and lentiviral engineered hemoglobin in cultured cells and sickle cell disease mice. The Journal of Gene Medicine. 2024. doi:10.1002/jgm.3567
BibTeX
@article{Wang2024,
author = {Wang, Xuejun and McKillop, William M and Dlugi, Theresa A and Faber, Mary L and Alvarez-Argote, Juliana and Chambers, Christopher B and Wilber, Andrew and Medin, Jeffrey A},
title = {A mass spectrometry assay for detection of endogenous and lentiviral engineered hemoglobin in cultured cells and sickle cell disease mice},
journal = {The Journal of Gene Medicine},
year = {2024},
doi = {10.1002/jgm.3567}
}
EUVIMED